Mohamad A. Salkeni

Oncology | Internal Medicine
8613 Route 29
Fairfax, VA 22031

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumors.

Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumors.

Journal: Cancer chemotherapy and pharmacology
Published: November 21, 2025

Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534.

Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534.

Journal: Investigational new drugs
Published: November 14, 2025

Correction: Margaryan et al. The Stem Cell Phenotype of Aggressive Breast Cancer Cells. Cancers 2019, 11, 340.

Correction: Margaryan et al. The Stem Cell Phenotype of Aggressive Breast Cancer Cells. Cancers 2019, 11, 340.

Journal: Cancers
Published: November 04, 2025

Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.

Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.

Journal: Breast cancer research : BCR
Published: May 24, 2024

Advanced Granulosa Cell Tumors of the Ovary: A Review with a Focus on Current and Novel Therapeutic Approaches.

Advanced Granulosa Cell Tumors of the Ovary: A Review with a Focus on Current and Novel Therapeutic Approaches.

Journal: Journal of immunotherapy and precision oncology
Published: October 21, 2023

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.

Journal: Breast cancer research : BCR
Published: October 05, 2023

Interleukin-10 in cancer immunotherapy: from bench to bedside.

Interleukin-10 in cancer immunotherapy: from bench to bedside.

Journal: Trends in cancer
Published: February 02, 2023

Resistance to Immunotherapy: Mechanisms and Means for Overcoming.

Resistance to Immunotherapy: Mechanisms and Means for Overcoming.

Journal: Advances in experimental medicine and biology
Published: January 01, 2022

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer.

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer.

Journal: Breast cancer (Dove Medical Press)
Published: June 24, 2021

Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.

Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 30, 2020

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 24, 2019

The Stem Cell Phenotype of Aggressive Breast Cancer Cells.

The Stem Cell Phenotype of Aggressive Breast Cancer Cells.

Journal: Cancers
Published: January 23, 2019
Showing 1-12 of 23

Last Updated: 09/26/2026